How to Buy Abbvie Stock
Abbvie Inc
Abbvie is a general drug manufacturer company located in Illinois, United States, which is part of the Healthcare sector, and is traded under the ticker ABBV on the NYSE exchange.
Abbvie stock last closed at $158.02, up 1.75% from the previous day, and has decreased 1.41% in one year. It has underperformed other stocks in the Drug Manufacturers - General industry by 0.05 percentage points. Abbvie stock is currently +17.85% from its 52-week low of $134.09, and -10.17% from its 52-week high of $175.91.
As of Mar 24, 2023, there are 1.77B shares of ABBV outstanding. The market value of ABBV is $279.60B. In the last 24 hours, 4.68M ABBV shares were traded.
How to Buy Abbvie Stock
Not sure how to invest in Abbvie stock? Here's how.
- Figure out where to buy Abbvie stock: You need to choose a stock brokerage, but don't worry - we've tried dozens of online brokerages and apps to help you figure out where to buy Abbvie stock.
- Sign up for a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Deposit funds into your brokerage account: Select your method of payment and add your details.
- Evaluate Abbvie stock: The Abbvie ticker symbol is ABBV. Is Abbvie stock a good investment? Should you buy shares of ABBV? How do ABBV's underlying business fundamentals look? Do top analysts think Abbvie is a good buy? Why has ABBV's stock price moved recently? (Hint: Our stock research website can help you decide if ABBV is a good stock to buy).
- Execute your ABBV purchase: Decide if you will purchase ABBV shares at the current market price or use a limit order to buy ABBV stock at a given price.
- Keep tabs on your investment in ABBV: Create a watchlist to watch your investment in Abbvie stock.
Step 1: Figure out where to buy Abbvie stock
You need a brokerage account in order to access the NYSE market and buy ABBV shares.
Our favorite brokerage: eToro
In our opinion, eToro is the best stock brokerage. Here's why:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to global markets: From Tech to Financial Services, New York to London — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of shares by signing up for an account with eToro now.
Open eToro AccountStep 2: Sign up for a brokerage account
Now that you've selected your brokerage, it's time to fill out some personal details so you are able to invest in ABBV stock today.
How to Create a New Brokerage Account on eToro
- Click here to get started.
- Input your personal details to start a new brokerage account.
- Submit your details by hitting the "Create Account" button.
Step 3: Deposit funds into your brokerage account
Now that you have opened your account on a good stock buying app, you need to deposit funds:
Check out the walkthrough below if you need help depositing money into your brokerage account.
Step 4: Evaluate Abbvie stock
After you have figured out the best place to buy Abbvie stock, it's important to research their stock before you buy, so you can comprehend the risk as well as the opportunity.
Abbvie Numbers
Abbvie Overview
WallStreetZen was created to help part-time investors perform better fundamental analysis quickly.
You can view all of the due diligence checks on ABBV's stock page.
How is ABBV stock valued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge ABBV's true value.
Using relative valuations metrics:
- ABBV could be undervalued based on its P/E ratio of 23.76x, relative to Drug Manufacturers - General industry P/E ratio of 26.79x
- ABBV may be overvalued based on its P/B ratio of 16.2x, relative to Drug Manufacturers - General industry P/B ratio of 4.89x
- ABBV could be overvalued based on its PEG ratio of 1.01x
You can access additional valuation analysis on ABBV's stock here.
ABBV Financial Health Overview
Passed Health Checks:
- Total ABBV debt is lower than 5 years ago, relative to shareholder equity.
- ABBV earnings of $15.51B is not enough to cover its interest payments.
- ABBV's operating cash flow of $24.94B allows it to safely service it's debt of $63.27B.
Failed Health Checks:
- There are more long-term liabilities than short-term assets on the ABBV balance sheet.
- ABBV has a relatively high debt to equity ratio of 7.04.
- ABBV profit margin has gone down from 20.5% to 20.4% in the past year.
- There are more short-term liabilities than short-term assets on the ABBV balance sheet.
Do analysts think it's a good time to buy ABBV stock
Out of 13 sell side analysts who give recommendations on ABBV, the consensus analyst rating on Abbvie is a Buy
Please keep in mind that analyst forecasts are not stock recommendations, nor are they financial advice.
Most Recent ABBV Analyst Upgrades/Downgrades
Vamil Divan, a top 5% analyst from Guggenheim initiates coverage on ABBV with a strong buy rating and announces their ABBV price target of $172.00, on Mar 1, 2023.
David Risinger, a top 9% analyst from SVB Leerink upgrades ABBV to a hold rating and raises their ABBV price target from $135.00 to $153.00, on Feb 10, 2023.
Risinger raised his price target on AbbVie Inc. by 13.3% following the release of the company's Q4 and FY 2022 earnings report on 2022/02/09.
Management's issuance of "2024 minimum trough EPS" guidance of $10.70 accounts for his PT update, the analyst told investors.
AbbVie should exceed management's "conservative" 2023 guidance, Risinger continued.
Although management's 2024 minimum EPS guidance was "encouraging," the analyst cautioned that uncertainty may continue to have an impact at least until 2H 2023 as Humira* biosimilar launches weigh on FY 2024 estimates.
Given the expected competition from generics for Linzess** in 2029/03 and Vraylar*** in 2029/09, financial pressures from 2029 to 2030 are also expected, Risinger added.
* From here: Adalimumab, sold under the brand name Humira, among others, is a monoclonal antibody used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis.
** From here: Linzess is an FDA-approved prescription medication used as a treatment for adults with Irritable Bowel Syndrome with Constipation (IBS-C) or Chronic Idiopathic Constipation (CIC). It is manufactured by AbbVie and Ironwood Pharmaceuticals. The patent will expire in 2029.
*** From here: Vraylar is a prescription medicine used in adults along with antidepressant medicines to treat major depressive disorder (MDD) for short-term treatment of manic or mixed episodes that happen with bipolar I disorder. Its patent will expire in 2029.
AbbVie reported:
For Q4 2022:
- EPS of $3.60, which beat the Zacks Consensus Estimate of $3.54 and, by 16.9%, Q4 2021’s $3.08.
- Revenues of $15.12B, which missed the Zacks Consensus Estimate of $15.35B but beat Q4 2021’s $14.89B by 1.6%.
For FY 2022:
- EPS of $13.77, which beat FY 2021’s $11.83 by 16.4%.
- Revenue of $58.05B, which beat FY 2021’s $56.2B by 3.3%.
For FY 2023, management guided:
- EPS of $10.70 to $11.10.
CEO Richard Gonzalez commented, "We have built a diverse portfolio of growth products with significant leadership positions, developed a robust pipeline of innovative assets, and created a culture of strong execution.
"Looking forward, we have a solid foundation that will allow us to absorb the U.S. Humira loss of exclusivity, return to strong top-line growth in 2025 and drive top-tier financial performance over the long term."
Steve Chesney, a top 28% analyst from Atlantic Equities maintains ABBV with a hold rating and lowers their ABBV price target from $157.00 to $154.00, on Feb 10, 2023.
Terence Flynn, a top 20% analyst from Morgan Stanley maintains ABBV with a strong buy rating and lowers their ABBV price target from $182.00 to $178.00, on Feb 10, 2023.
Christopher Raymond, a bottom 18% analyst from Piper Sandler maintains ABBV with a strong buy rating and raises their ABBV price target from $157.00 to $163.00, on Feb 10, 2023.
You can dive deeper into what analysts are projecting on the Abbvie stock forecast page.
ABBV Momentum
ABBV Earnings
Last year, ABBV earnings were $11.84B. During the past 5 year, ABBV's earnings have gone up by 14.97% per year. This was slower than the Drug Manufacturers - General industry average of 25.43%.
Last year, ABBV revenue was $58.05B. In the last 5 year, ABBV's revenue has grown by 15.52% per year. This was faster than the Drug Manufacturers - General industry average of 8.32%.
You can analyze ABBV's earnings and revenue performance here.
Who is buying/selling ABBV?
Over the past year, insiders at ABBV have sold more shares than they have bought.
Jeffrey Ryan Stewart, EVP CHIEF COMMERCIAL OFFICER of ABBV, was the latest ABBV insider to sell. They sold $4,768,335.05 worth of ABBV stock on Mar 13, 2023.
Get more info about who owns ABBV stock here.
Does ABBV stock generate passive income?
Abbvie pays a dividend of 3.61%, compared to the Drug Manufacturers - General industry's average dividend yield of 3.16%. If you owned $1,000 of ABBV stock, you would have been paid $36.13 last year.
Abbvie dividend payments have consistently grown over the past decade and have remained stable.
Get more info about Abbvie dividend yield and history here.
ABBV Social Trading Data
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other traders have to say.
Step 5: Execute your ABBV purchase
You have two main order types:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are mostly fine. - Limit order: A limit order is an order to buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at a particular price limit, place a limit order.
Click the Open Trade button and eToro will place the order.
If you require more info about buying stocks on eToro, click the how to video below:
Step 6: Keep tabs on your investment in ABBV
Now that you own some ABBV stock, you'll want to keep up with your shares.
Start a watchlist to keep track of your ABBV stock.
ABBV Feed
How to Buy Stock in Abbvie
To summarize, here are the 6 steps to buy stock in Abbvie:
- Figure out where to buy Abbvie stock
- Sign up for a brokerage account
- Deposit funds into your brokerage account
- Evaluate Abbvie stock
- Execute your ABBV purchase
- Keep tabs on your investment in ABBV
If you require a brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you want to keep an eye on your investment in Abbvie, get started below.
Other "How To" Guides You Might Find Useful
FAQ
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.